ORGANOGENESIS HOLDINGS INC (ORGO) Fundamental Analysis & Valuation

NASDAQ:ORGO • US68621F1021

2.9 USD
+0.03 (+1.05%)
At close: Mar 5, 2026
2.86 USD
-0.04 (-1.38%)
After Hours: 3/5/2026, 8:13:53 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ORGO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Taking everything into account, ORGO scores 5 out of 10 in our fundamental rating. ORGO was compared to 520 industry peers in the Biotechnology industry. ORGO scores excellent on profitability, but there are some minor concerns on its financial health. ORGO is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

7

1. ORGO Profitability Analysis

1.1 Basic Checks

  • In the past year ORGO was profitable.
  • ORGO had a negative operating cash flow in the past year.
  • ORGO had positive earnings in 4 of the past 5 years.
  • ORGO had a positive operating cash flow in 4 of the past 5 years.
ORGO Yearly Net Income VS EBIT VS OCF VS FCFORGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M

1.2 Ratios

  • With an excellent Return On Assets value of 2.65%, ORGO belongs to the best of the industry, outperforming 88.65% of the companies in the same industry.
  • ORGO has a Return On Equity of 3.65%. This is amongst the best in the industry. ORGO outperforms 89.81% of its industry peers.
  • ORGO has a better Return On Invested Capital (8.83%) than 93.27% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for ORGO is significantly below the industry average of 19.05%.
  • The 3 year average ROIC (5.16%) for ORGO is below the current ROIC(8.83%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 2.65%
ROE 3.65%
ROIC 8.83%
ROA(3y)1.41%
ROA(5y)5.82%
ROE(3y)2.05%
ROE(5y)10.24%
ROIC(3y)5.16%
ROIC(5y)7.22%
ORGO Yearly ROA, ROE, ROICORGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100

1.3 Margins

  • ORGO's Profit Margin of 2.81% is amongst the best of the industry. ORGO outperforms 88.46% of its industry peers.
  • In the last couple of years the Profit Margin of ORGO has declined.
  • ORGO's Operating Margin of 9.90% is amongst the best of the industry. ORGO outperforms 90.77% of its industry peers.
  • ORGO's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 75.62%, ORGO belongs to the top of the industry, outperforming 83.85% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ORGO has remained more or less at the same level.
Industry RankSector Rank
OM 9.9%
PM (TTM) 2.81%
GM 75.62%
OM growth 3Y26.04%
OM growth 5Y4.64%
PM growth 3Y1.07%
PM growth 5Y-6.94%
GM growth 3Y-0.48%
GM growth 5Y0.38%
ORGO Yearly Profit, Operating, Gross MarginsORGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. ORGO Health Analysis

2.1 Basic Checks

  • ORGO has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • ORGO has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ORGO has less shares outstanding
  • ORGO has a worse debt/assets ratio than last year.
ORGO Yearly Shares OutstandingORGO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
ORGO Yearly Total Debt VS Total AssetsORGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • ORGO has an Altman-Z score of 3.13. This indicates that ORGO is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 3.13, ORGO is in the better half of the industry, outperforming 67.50% of the companies in the same industry.
  • ORGO has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
  • ORGO has a Debt to Equity ratio (0.03) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 3.13
ROIC/WACC1.03
WACC8.58%
ORGO Yearly LT Debt VS Equity VS FCFORGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M 400M

2.3 Liquidity

  • ORGO has a Current Ratio of 3.62. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 3.62, ORGO perfoms like the industry average, outperforming 43.27% of the companies in the same industry.
  • ORGO has a Quick Ratio of 3.32. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
  • ORGO has a Quick ratio (3.32) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.62
Quick Ratio 3.32
ORGO Yearly Current Assets VS Current LiabilitesORGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ORGO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 52.94% over the past year.
  • ORGO shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 16.72% yearly.
  • ORGO shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.04%.
  • The Revenue has been growing by 10.77% on average over the past years. This is quite good.
EPS 1Y (TTM)52.94%
EPS 3Y25.99%
EPS 5Y16.72%
EPS Q2Q%416.67%
Revenue 1Y (TTM)17.04%
Revenue growth 3Y7.76%
Revenue growth 5Y10.77%
Sales Q2Q%78.13%

3.2 Future

  • The Earnings Per Share is expected to grow by 12.92% on average over the next years. This is quite good.
  • ORGO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.93% yearly.
EPS Next Y-109.81%
EPS Next 2Y12.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-8.34%
Revenue Next 2Y3.93%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ORGO Yearly Revenue VS EstimatesORGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
ORGO Yearly EPS VS EstimatesORGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

Find the best growth stocksShow best growing peers

4

4. ORGO Valuation Analysis

4.1 Price/Earnings Ratio

  • ORGO is valuated reasonably with a Price/Earnings ratio of 11.15.
  • Compared to the rest of the industry, the Price/Earnings ratio of ORGO indicates a rather cheap valuation: ORGO is cheaper than 96.73% of the companies listed in the same industry.
  • ORGO's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.74.
  • ORGO is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 11.15
Fwd PE N/A
ORGO Price Earnings VS Forward Price EarningsORGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ORGO indicates a rather cheap valuation: ORGO is cheaper than 99.04% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 4.05
ORGO Per share dataORGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • ORGO has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as ORGO's earnings are expected to grow with 12.92% in the coming years.
PEG (NY)N/A
PEG (5Y)0.67
EPS Next 2Y12.92%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ORGO Dividend Analysis

5.1 Amount

  • ORGO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ORGO Fundamentals: All Metrics, Ratios and Statistics

ORGANOGENESIS HOLDINGS INC

NASDAQ:ORGO (3/5/2026, 8:13:53 PM)

After market: 2.86 -0.04 (-1.38%)

2.9

+0.03 (+1.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners54.62%
Inst Owner Change-0.51%
Ins Owners31.34%
Ins Owner Change1.22%
Market Cap373.06M
Revenue(TTM)564.17M
Net Income(TTM)15.85M
Analysts85
Price Target8.67 (198.97%)
Short Float %19.4%
Short Ratio15.28
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)106.05%
Min EPS beat(2)44.72%
Max EPS beat(2)167.38%
EPS beat(4)2
Avg EPS beat(4)16.53%
Min EPS beat(4)-73%
Max EPS beat(4)167.38%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)19.19%
Min Revenue beat(2)10.3%
Max Revenue beat(2)28.08%
Revenue beat(4)2
Avg Revenue beat(4)6.94%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)28.08%
Revenue beat(8)6
Avg Revenue beat(8)7.04%
Revenue beat(12)7
Avg Revenue beat(12)4.32%
Revenue beat(16)7
Avg Revenue beat(16)2.3%
PT rev (1m)0%
PT rev (3m)6.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)23.53%
EPS NY rev (1m)0%
EPS NY rev (3m)216.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.66%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.49%
Valuation
Industry RankSector Rank
PE 11.15
Fwd PE N/A
P/S 0.66
P/FCF N/A
P/OCF N/A
P/B 0.86
P/tB 0.94
EV/EBITDA 4.05
EPS(TTM)0.26
EY8.97%
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS4.39
BVpS3.37
TBVpS3.08
PEG (NY)N/A
PEG (5Y)0.67
Graham Number4.44
Profitability
Industry RankSector Rank
ROA 2.65%
ROE 3.65%
ROCE 11.21%
ROIC 8.83%
ROICexc 10.88%
ROICexgc 12%
OM 9.9%
PM (TTM) 2.81%
GM 75.62%
FCFM N/A
ROA(3y)1.41%
ROA(5y)5.82%
ROE(3y)2.05%
ROE(5y)10.24%
ROIC(3y)5.16%
ROIC(5y)7.22%
ROICexc(3y)6.81%
ROICexc(5y)10.02%
ROICexgc(3y)7.75%
ROICexgc(5y)12.19%
ROCE(3y)6.54%
ROCE(5y)9.15%
ROICexgc growth 3Y14.91%
ROICexgc growth 5Y-14%
ROICexc growth 3Y18.93%
ROICexc growth 5Y-6.02%
OM growth 3Y26.04%
OM growth 5Y4.64%
PM growth 3Y1.07%
PM growth 5Y-6.94%
GM growth 3Y-0.48%
GM growth 5Y0.38%
F-Score2
Asset Turnover0.94
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA 0.17
Cap/Depr 76.1%
Cap/Sales 2.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.62
Quick Ratio 3.32
Altman-Z 3.13
F-Score2
WACC8.58%
ROIC/WACC1.03
Cap/Depr(3y)97.86%
Cap/Depr(5y)180.1%
Cap/Sales(3y)3.4%
Cap/Sales(5y)4.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.94%
EPS 3Y25.99%
EPS 5Y16.72%
EPS Q2Q%416.67%
EPS Next Y-109.81%
EPS Next 2Y12.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)17.04%
Revenue growth 3Y7.76%
Revenue growth 5Y10.77%
Sales Q2Q%78.13%
Revenue Next Year-8.34%
Revenue Next 2Y3.93%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y159.64%
EBIT growth 3Y35.82%
EBIT growth 5Y15.91%
EBIT Next Year-3.85%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-685.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-172.56%
OCF growth 3YN/A
OCF growth 5YN/A

ORGANOGENESIS HOLDINGS INC / ORGO FAQ

Can you provide the ChartMill fundamental rating for ORGANOGENESIS HOLDINGS INC?

ChartMill assigns a fundamental rating of 5 / 10 to ORGO.


Can you provide the valuation status for ORGANOGENESIS HOLDINGS INC?

ChartMill assigns a valuation rating of 4 / 10 to ORGANOGENESIS HOLDINGS INC (ORGO). This can be considered as Fairly Valued.


What is the profitability of ORGO stock?

ORGANOGENESIS HOLDINGS INC (ORGO) has a profitability rating of 7 / 10.


What is the financial health of ORGANOGENESIS HOLDINGS INC (ORGO) stock?

The financial health rating of ORGANOGENESIS HOLDINGS INC (ORGO) is 5 / 10.